Phase I/II Trial of Liver Derived Mesenchymal Stem Cells in Pediatric Liver Based Metabolic Disorders: A Prospective, Open Label, Multicenter, Partially Randomized, Safety Study of One Cycle of Heterologous Human Adult Liver-Derived Progenitor Cells (HepaStem®) in Urea Cycle Disorders and Crigler-Najjar Syndrome patients

Françoise Smets, Dries Dobbelaere, Patrick McKiernan, Carlo Dionisi-Vici, Pierre Broué, Emmanuel Jacquemin, Ana Isabel Lopes, Isabel Gonçalves, Hanna Mandel, Joanna Pawlowska, Diana Kamińska, Eyal Shteyer, Giuliano Torre, Riki Shapiro, François Eyskens, Philippe Clapuyt, Paul Gissen, Danièle Pariente, Stephanie Grunewald, Marc YudkoffMaria Mercedes Binda, Mustapha Najimi, Nathalie Belmonte, Beatrice De Vos, Joelle Thonnard, Etienne Sokal

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Phase I/II Trial of Liver Derived Mesenchymal Stem Cells in Pediatric Liver Based Metabolic Disorders: A Prospective, Open Label, Multicenter, Partially Randomized, Safety Study of One Cycle of Heterologous Human Adult Liver-Derived Progenitor Cells (HepaStem®) in Urea Cycle Disorders and Crigler-Najjar Syndrome patients'. Together they form a unique fingerprint.

Medicine & Life Sciences